Tech Stocks
Cannabis Stocks
Index Funds
International
Short
Stock Picks

Username or Email Address

Password

Remember Me

Lost Password?

Amazon vs. Costco: Which Stock Is a Better Buy?

Amazon vs. Costco: Which Stock Is a Better Buy?

Cross Staff Loads Up on 289,000 Shares of AKRE

Cross Staff Loads Up on 289,000 Shares of AKRE

Prediction: This Artificial Intelligence (AI) Stock Will Join Nvidia, Apple, and Alphabet in the $3 Trillion Club Before 2028

The billion-dollar infrastructure deals powering the AI boom

AI Boom May Be Creating Hidden Risks In Housing Market

Cisco’s Secure AI Factory Links Sovereign Data Push To Valuation Story

OutPerformDaily

Tech Stocks
Cannabis Stocks
Index Funds
International
Short
Stock Picks

Tech Stocks
Cannabis Stocks
Index Funds
International
Short
Stock Picks

Tirzepatide outpacing Wegovy in the obesity space

January 2, 2025

Novo Nordisk’s Wegovy made a significant impact on the obesity market when it launched in 2021.

You may also like

Amazon vs. Costco: Which Stock Is a Better Buy?

Amazon vs. Costco: Which Stock Is a Better Buy?

February 28, 2026

Cross Staff Loads Up on 289,000 Shares of AKRE

Cross Staff Loads Up on 289,000 Shares of AKRE

February 28, 2026

AMD Ties Meta And Nutanix Deals To Long Term AI Growth Narrative

AMD Ties Meta And Nutanix Deals To Long Term AI Growth Narrative

February 28, 2026

Indices by TradingView

Categories

3rdPartyFeeds
Cannabis Stocks
Index Funds
International
News
Short
Stock Picks
Tech Stocks
Uncategorized

Indices by TradingView

While subscribers receive the benefit of Outperformdaily opinions, none of the information contained therein constitutes a recommendation from Outperformdaily that any particular security, portfolio of securities, transaction, option, or investment strategy is suitable for any specific person. You further understand that we will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent any of the information contained in Outperformdaily may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Outperformdaily’s past results are not necessarily indicative of future performance. All investments are subject to loss. Our employees and writters typically personally invest in all recommendations, but they are not obligated too. Our employees and writters are prohibited from taking an opposite position from which they write about.